Organoid Platform in Preclinical Investigation of Personalized Immunotherapy Efficacy in Appendiceal Cancer: Feasibility Study
2021 · Clinical Cancer Research · 68 citations
https://doi.org/10.1158/1078-0432.ccr-21-0982
R
Richard A. Erali
Forest Institute(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
54
Papers
706
Citations
10
h-index
10
i10-index
Richard A. Erali is an academic researcher from Forest Institute. The author has contributed to research in topics: Intraperitoneal and Appendiceal Malignancies & Ovarian cancer diagnosis and treatment & Pancreatic and Hepatic Oncology Research. The author has an h-index of 10, co-authored 46 publications.
ORCID: 0000-0002-4649-0450Papers by this author
worksPatient-Specific Sarcoma Organoids for Personalized Translational Research: Unification of the Operating Room with Rare Cancer Research and Clinical Implications
2022 · Annals of Surgical Oncology · 57 citations
https://doi.org/10.1245/s10434-022-12086-y
Application of immune enhanced organoids in modeling personalized Merkel cell carcinoma research
2022 · Scientific Reports · 20 citations
https://doi.org/10.1038/s41598-022-17921-6
Cisplatin exhibits superiority over MMC as a perfusion agent in a peritoneal mesothelioma patient specific organoid HIPEC platform
2023 · Scientific Reports · 8 citations
https://doi.org/10.1038/s41598-023-38545-4
Biofabrication of pheochromocytoma and paraganglioma tumor organoids and assessment of response to systemic therapy
2025 · Scientific Reports · 1 citations
https://doi.org/10.1038/s41598-025-19806-w
Persistent opioid use after curative‐intent hepatectomy for neoplastic disease
2021 · Journal of Surgical Oncology · 0 citations
https://doi.org/10.1002/jso.26472
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat